Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Mortality and Rehospitalization rate.
- Who it may be relevant to
- Registry conditions: Heart Failure. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Registry for Longitudinal Mortality and Therapy in Patients With Heart Failure (GREARTWAL Study)
Overview
The purpose of this registry is to compile a large clinical database on the medical management of patients hospitalized with acute heart failure, using information collected from hospitals across China.
Detailed description
Registry for Longitudinal mortality and therapy in patients with Heart Failure is a large, multicenter, prospective, open-label registry of the management of patients treated in the hospital for acute heart failure in China. The objective of this study is to investigate the clinical features and prognosis of patients with heart failure, and discover the characteristics of high-risk heart failure patients, and elucidate critical factors which predict the development and outcomes of symptomatic heart failure patients.
1. To elucidate the clinical characteristics and prognostic risks of patients with heart failure. 2. To study the characteristics of high-risk heart failure patients and predict the key factors for the development of symptomatic heart failure patients. 3. To elucidate the compliance of patients with heart failure and the incidence of adverse drug effects. 4. To investigate the effect of self-management on outcomes in patients with heart failure. 5. To elucidate critical factors associated with the development and outcomes of heart failure. 6. To investigate hospitalization expenses for heart failure.
Interventions
- Other Mortality and Rehospitalization rate
Mortality and Re-hospitalization of acute decompensated heart failure
Primary outcome measures
- Mortality of acute decompensated heart failure [Time frame: 10 years]
- Re-hospitalization rate [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
\- 1. 18 years and older. 2. Meet the diagnostic criteria of China 2018 or JACC/AHA 2017 or ESC 2016 heart failure guidelines.
3\. Agree to be tested and sign an informed consent certificate.
Exclusion criteria
- 1\. Age<18 years old. 2. Patients who refused to participate. 3. Patients may have a life expectancy of less than 1 years due to non- heart failure clinical conditions.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Shanghai Tenth People's Hospital, Tongji University — Shanghai
Publications
- Su Y, Ma M, Zhang H, Pan X, Zhang X, Zhang F, Lv Y, Yan C. Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study. Exp Ther Med. 2020 Nov;20(5):101. doi: 10.3892/etm.2020.9231. Epub 2020 Sep 17. PMID 32973950
Identifiers
NCT: NCT04062500 · GREARTWAL